Lori Elizabeth Mochan
Director/Board Member chez NIGHTSTAR THERAPEUTICS PLC
Profil
Lori Elizabeth Mochan is currently a Director at NightstaRx Ltd., Amicus Therapeutics UK Ltd., Nightstar Therapeutics Ltd., and Tungsten Bidco Ltd.
She was also a Co-Managing Director at Amicus Therapeutics GmbH.
In the past, she worked as a Director at Amicus Therapeutics International Holding Ltd.
from 2018 to 2020.
Postes actifs de Lori Elizabeth Mochan
| Sociétés | Poste | Début |
|---|---|---|
| NIGHTSTAR THERAPEUTICS PLC | Director/Board Member | 21/04/2020 |
Amicus Therapeutics UK Ltd.
 Amicus Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a private company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution. | Director/Board Member | 03/05/2018 |
Amicus Therapeutics GmbH
 Amicus Therapeutics GmbH BiotechnologyHealth Technology Part of Amicus Therapeutics, Inc., Amicus Therapeutics GmbH is a German biotechnology company that develops therapies for rare and orphan diseases. The private company is based in Munich, Germany. The CEOs are Lori Elizabeth Mochan, Christian Ruppenthal, Anita Jane Clifford. The company was founded in 2002. | Chief Executive Officer | - |
Tungsten Bidco Ltd.
 Tungsten Bidco Ltd. Financial ConglomeratesFinance Founded in 2019, Tungsten Bidco Ltd. is a British company that functions as an investment holding company. Part of Biogen, Inc., the private company is based in Maidenhead, UK. | Director/Board Member | 21/04/2020 |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Director/Board Member | 21/04/2020 |
Anciens postes connus de Lori Elizabeth Mochan
| Sociétés | Poste | Fin |
|---|---|---|
Amicus Therapeutics International Holding Ltd.
 Amicus Therapeutics International Holding Ltd. Financial ConglomeratesFinance Founded in 2016, Amicus Therapeutics International Holding Ltd. is a British company that functions as an investment holding company. Part of Amicus Therapeutics, Inc., the private company is based in Marlow, UK. | Director/Board Member | 21/02/2020 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Amicus Therapeutics UK Ltd.
Amicus Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a private company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution. | Commercial Services |
Amicus Therapeutics International Holding Ltd.
Amicus Therapeutics International Holding Ltd. Financial ConglomeratesFinance Founded in 2016, Amicus Therapeutics International Holding Ltd. is a British company that functions as an investment holding company. Part of Amicus Therapeutics, Inc., the private company is based in Marlow, UK. | Finance |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Amicus Therapeutics GmbH
Amicus Therapeutics GmbH BiotechnologyHealth Technology Part of Amicus Therapeutics, Inc., Amicus Therapeutics GmbH is a German biotechnology company that develops therapies for rare and orphan diseases. The private company is based in Munich, Germany. The CEOs are Lori Elizabeth Mochan, Christian Ruppenthal, Anita Jane Clifford. The company was founded in 2002. | Health Technology |
Tungsten Bidco Ltd.
Tungsten Bidco Ltd. Financial ConglomeratesFinance Founded in 2019, Tungsten Bidco Ltd. is a British company that functions as an investment holding company. Part of Biogen, Inc., the private company is based in Maidenhead, UK. | Finance |
